# 64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation

> **NCT05728372** · EARLY_PHASE1 · WITHDRAWN · sponsor: **City of Hope Medical Center**

## Conditions studied

- Metastatic Malignant Solid Neoplasm

## Interventions

- **DRUG:** Copper Cu 64-DOTA-pembrolizumab
- **PROCEDURE:** Positron Emission Tomography
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT05728372
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-08-25
- **Primary completion:** 2026-11-08
- **Final completion:** 2026-11-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** withdrawn per PI
- **Last updated:** 2023-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05728372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05728372, "64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05728372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*